Global Menopausal Hot Flashes Market Size study & Forecast, by Treatment Type (Hormonal Treatment and Non-hormonal Treatment) and Regional Analysis, 2022-2029

Global Menopausal Hot Flashes Market Size study & Forecast, by Treatment Type (Hormonal Treatment and Non-hormonal Treatment) and Regional Analysis, 2022-2029

Global Menopausal Hot Flashes Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than 3.4% over the forecast period 2022-2029. Menopausal hot flashes are often brought on by the intricate hormonal adjustments brought on by the lowering oestrogen levels as menopause occurs in women. The body feels warm because of declining levels' effects on thermoregulation. On average, the illness can persist over 7 years, and in the most severe cases, it can last up to 10 years. Although it is a normal condition, it can be brought on by factors like drinking alcohol, eating hot food, smoking, being stressed, and other things. The market growth is driven by key factors such as increasing awareness about menopause and its treatment and increasing research supporting advantages of dietary supplements.

In the United States, roughly 1.3 million women cease menstruation each year, beginning between the ages of 51 and 52, according to the February 2022 version of Menopause (Nursing) by Kimberly Peacock et al. About 5% of women between the ages of 40 and 45 undergo early menopause, according to the same source. The market is also expanding as a result of the growing emphasis on research aimed at the development of treatments for hot flashes. For instance, Acer Therapeutics Inc. received FDA approval for its investigational new drug (IND) application for its selective non-peptide neurokinin 3 receptors (NK3R) antagonist, ACER-801 (osanetant), for the possible treatment of induced Vasomotor Symptoms in December 2021. (iVMS). However, side Effects Associated with Hormonal Products stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Menopausal Hot Flashes Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the overall market share owing to increased incidence of menopause and presence of a large percentage of older women in the region. However, Asia Pacific is expected to be the fastest growing region due to increased medical tourism and growing public awareness in the region.

Major market player included in this report are:
Bristol-Myers Squibb Company
Novartis AG
Teva Pharmaceutical Industries Ltd
Hisamitsu Pharmaceutical Co. Inc.
AstraZeneca PLC
Agile Therapeutics
Novo Nordisk Corporation
Pfizer Inc.
Merck & Co. Inc.
Ferring BV

Recent Developments in the Market:

The U.S. Food and Drug Administration received a new drug application (NDA) for fezolinetant from Astellas Pharma Inc. in June 2022. (FDA). For the treatment of mild to severe vasomotor symptoms (VMS) related to menopause, the experimental oral, nonhormonal chemical fezolinetant is appealing for approval.

In order to increase the number of drugs in its pipeline, Bayer, a leading global supplier of healthcare for women, purchased KaNDy Therapeutics Ltd. in August 2020. For the treatment of menopausal symptoms, KaNDy Therapeutics Ltd. has finished the Phase IIb trials of NT-814, a first-in-class, non-hormonal neurokinin-1,3 receptor antagonist.
Global Menopausal Hot Flashes Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage
Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered
Treatment Type, Region
Regional Scope
North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope
Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below.
By Treatment Type:
Non-hormonal Treatment
Hormonal Treatment
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australi.
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Bristol-Myers Squibb Company
Novartis AG
Teva Pharmaceutical Industries Ltd
Hisamitsu Pharmaceutical Co. Inc.
AstraZeneca PLC
Agile Therapeutics
Novo Nordisk Corporation
Pfizer Inc.
Merck & Co. Inc.
Ferring BV

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.